San Diego, CA -- (SBWIRE) -- 08/18/2014 -- An investigation on behalf of current long-term investors in shares Osiris Therapeutics, Inc. (NASDAQ:OSIR) shares was announced over potential breaches of fiduciary duties by certain officers and directors at Osiris Therapeutics, Inc.

Investors who purchased shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) and currently hold any of those NASDAQ:OSIR shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Osiris Therapeutics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

On August 13, 2013, Osiris Therapeutics, Inc. announced the results of the planned interim analysis of the data from its multi-center, randomized, controlled clinical trial (Protocol 302) comparing the safety and efficacy of Grafix ® to standard of care. Shares of Osiris Therapeutics, Inc. jumped from $10.66 per share on August 12, 2013 to $25.44 per share on August 13, 2013.

Then on October 21, 2013, Osiris Therapeutics, Inc. announced that it had reached agreement with the United States Food and Drug Administration (“FDA”) regarding the regulatory pathway for its Biosurgery products, Grafix® and Ovation®. Osiris Therapeutics, Inc. said the commitments in this agreement will resolve recent concerns FDA raised in an untitled letter dated September 26, 2013. Shares of Osiris Therapeutics, Inc. declined from $19.64 per share on October 4, 2013, respectively $17.94 per share on October 18, 2013, to as low as $13.41 per share on October 22, 2013.

Those who purchased shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com